David Arkowitz
David Arkowitz's purchase track record
David Arkowitz has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/10/2025 | IBIO | $50K | -52.9% | -68.2% | +7.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
MCRB to Present Preclinical Data on SER-428 at IDWeek 2026. Seres Therapeutics announced it will present preclinical data for SER-428, an investigational live biotherapeutic intended to reduce the risk of bloodstream infections in critically ill patients, at the upcoming IDWeek 2026 conference. The data will focus on early-stage results that support the development of the oral liquid LBP. The stock is currently trading near its $7.60 support level with an RSI of 22.8, indicating limited recent price momentum.
Transaction History
| IBIO | ▲ Buy | Open Market | 18,382 | $50K | 1/10/2025 | View on chart |
| MCRB | ▼ Sell | Open Market | 3,939 | $4K | 2/16/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 10,625 | — | 2/15/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 4,066 | $5K | 10/30/2023 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 13,209 | $0 | 10/27/2023 | View on chart |
| MCRB | ▲ Buy | Grant | 42,500 | $0 | 4/27/2023 | View on chart |
| MCRB | ▲ Buy | Grant | 42,500 | $0 | 10/27/2022 | View on chart |
| MCRB | ▲ Buy | Grant | 63,492 | $200K | 7/5/2022 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 5,000 | $0 | 6/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
iBio to Present Data at 2026 EASD Annual Meeting
iBio Inc. announced it will present at the 2026 EASD Annual Meeting. This event is relevant as it provides a platform to share updates on the company's medical technology. The stock is currently trading near its 52-week low, with an RSI of 24.6 indicating oversold conditions. Analysts maintain an average price target of $5.69, significantly above the current market price.
iBio to Present Data at 2026 EASD Annual Meeting. iBio Inc. announced it will present at the 2026 EASD Annual Meeting. This event is relevant as it provides a platform to share updates on the company's medical technology. The stock is currently trading near its 52-week low, with an RSI of 24.6 indicating oversold conditions. Analysts maintain an average price target of $5.69, significantly above the current market price.